M-CSF accelerates neointimal formation in the early phase after vascular injury in mice the critical role of the SDF-1-CXCR4 system

被引:75
作者
Shiba, Yuji
Takahashi, Masafumi
Yoshioka, Toru
Yajima, Noriyuki
Morimoto, Hajime
Izawa, Atsushi
Ise, Hirohiko
Hatake, Kiyohiko
Motoyoshi, Kazuo
Ikeda, Uichi
机构
[1] Shinshu Univ, Grad Sch Med, Dept Organ Regenerat, Div Cardiovasc Sci, Nagano 3908621, Japan
[2] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
关键词
angioplasty; cytokines; inflammation; restenosis; vascular biology;
D O I
10.1161/01.ATV.0000250606.70669.14
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Since the macrophage colony-stimulating factor ( M-CSF) has been shown to stimulate differentiation and proliferation of monocyte/macrophage lineage and to be involved in the process of neointimal formation after vascular injury, we tested the effects of M-CSF on the recruitment of bone marrow-derived progenitor cells in neointimal formation after vascular injury in mice. Methods and Results-Wire-mediated vascular injury was produced in the femoral artery of C57BL/6 mice. Recombinant human M-CSF [ 500 mu g/( kg.day)] or saline ( control) was administered for 10 consecutive days, starting 4 days before the injury. Treatment with M-CSF accelerated neointimal formation in the early phase after injury, and this neointimal lesion mainly consisted of bone marrow - derived cells. M-CSF treatment had no effect on the mobilization of endothelial progenitor cells ( EPCs: CD34(+)/Flk-1(+)) and reendothelialization after injury. The stromal cell-derived factor-1 ( SDF-1) was markedly expressed in the neointima and media after injury, whereas CXCR4(+) cells were observed in the neointima. Further, a novel CXCR4 antagonist, AMD3100, significantly attenuated the M-CSF - induced neointimal formation. Conclusions-These findings suggest that M-CSF accelerated neointimal formation after vascular injury via the SDF-1-CXCR4 system, and the inhibition of this system has therapeutic potential for the treatment of cardiovascular diseases.
引用
收藏
页码:283 / 289
页数:7
相关论文
共 32 条
[1]   Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist [J].
Broxmeyer, HE ;
Orschell, CM ;
Clapp, DW ;
Hangoc, G ;
Cooper, S ;
Plett, PA ;
Liles, WC ;
Li, XX ;
Graham-Evans, B ;
Campbell, TB ;
Calandra, G ;
Bridger, G ;
Dale, DC ;
Srour, EF .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08) :1307-1318
[2]  
CAPOCCIA BJ, 2006, BLOOD
[3]  
CLINTON SK, 1992, AM J PATHOL, V140, P301
[4]  
DENG Z, 2006, INT J CARDIOL
[5]   Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? [J].
Dimmeler, S ;
Zeiher, AM .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2004, 82 (10) :671-677
[6]   Increased expression of macrophage colony-stimulating factor after coronary artery balloon injury is inhibited by intracoronary brachytherapy [J].
Finkelstein, A ;
Makkar, R ;
Doherty, TM ;
Vegesna, VR ;
Tripathi, P ;
Liu, M ;
Bergman, J ;
Fishbein, M ;
Hausleiter, J ;
Takizawa, K ;
Rukshin, V ;
Shah, PK ;
Rajavashisth, TB .
CIRCULATION, 2002, 105 (20) :2411-2415
[7]   The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone [J].
Flomenberg, N ;
Devine, SM ;
DiPersio, JF ;
Liesveld, JL ;
McCarty, JM ;
Rowley, SD ;
Vesole, DH ;
Badel, K ;
Calandra, G .
BLOOD, 2005, 106 (05) :1867-1874
[8]   Autologous culture-modified mononuclear cells confer vascular protection after arterial injury [J].
Gulati, R ;
Jevremovic, D ;
Peterson, TE ;
Witt, TA ;
Kleppe, LS ;
Mueske, CS ;
Lerman, A ;
Vile, RG ;
Simari, RD .
CIRCULATION, 2003, 108 (12) :1520-1526
[9]   CD34- blood-derived human endothelial cell progenitors [J].
Harraz, M ;
Jiao, CH ;
Hanlon, HD ;
Hartley, RS ;
Schatteman, GC .
STEM CELLS, 2001, 19 (04) :304-312
[10]   Chemokine expression in coronary circulation after coronary angioplasty as a prognostic factor for restenosis [J].
Hojo, Y ;
Ikeda, U ;
Katsuki, T ;
Mizuno, O ;
Fukazawa, H ;
Fujikawa, H ;
Shimada, K .
ATHEROSCLEROSIS, 2001, 156 (01) :165-170